Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 36 citing articles:

Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis
Hansje‐Eva Teulings, Jacqueline Limpens, Sophia N. Jansen, et al.
Journal of Clinical Oncology (2015) Vol. 33, Iss. 7, pp. 773-781
Closed Access | Times Cited: 565
Induction of CD8+T-Cell Responses Against Novel Glioma–Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma
Hideho Okada, Paweł Kaliński, Ryo Ueda, et al.
Journal of Clinical Oncology (2010) Vol. 29, Iss. 3, pp. 330-336
Open Access | Times Cited: 549
Therapeutic cancer vaccines: are we there yet?
Christopher A. Klebanoff, Nicolas Acquavella, Zhiya Yu, et al.
Immunological Reviews (2010) Vol. 239, Iss. 1, pp. 27-44
Open Access | Times Cited: 272
Trial watch
Erika Vacchelli, Ilio Vitale, Alexander Eggermont, et al.
OncoImmunology (2013) Vol. 2, Iss. 10, pp. e25771-e25771
Open Access | Times Cited: 244
Trial watch
Lorenzo Galluzzi, Laura Senovilla, Erika Vacchelli, et al.
OncoImmunology (2012) Vol. 1, Iss. 7, pp. 1111-1134
Open Access | Times Cited: 148
Optimized Peptide Vaccines Eliciting Extensive CD8 T-Cell Responses with Therapeutic Antitumor Effects
Hyun-Il Cho, Esteban Celis
Cancer Research (2009) Vol. 69, Iss. 23, pp. 9012-9019
Open Access | Times Cited: 133
Safety and tolerability evaluation of the use of Montanide ISA™51 as vaccine adjuvant: A systematic review
Eva van Doorn, Heng Liu, Anke Huckriede, et al.
Human Vaccines & Immunotherapeutics (2015) Vol. 12, Iss. 1, pp. 159-169
Open Access | Times Cited: 114
Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Vaccination with an Allogeneic Whole-Cell Melanoma Vaccine
Mark B. Faries, Eddy C. Hsueh, Xing Ye, et al.
Clinical Cancer Research (2009) Vol. 15, Iss. 22, pp. 7029-7035
Open Access | Times Cited: 89
First clinical trial of cancer vaccine therapy with artificially synthesized helper/ killer-hybrid epitope long peptide of MAGE-A4 cancer antigen
Norihiko Takahashi, Takayuki Ohkuri, Shigenori Homma, et al.
Cancer Science (2012) Vol. 103, Iss. 1, pp. 150-153
Open Access | Times Cited: 60
Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma
Christoph Höeller, Olivier Michielin, Paolo A. Ascierto, et al.
Cancer Immunology Immunotherapy (2016) Vol. 65, Iss. 9, pp. 1015-1034
Open Access | Times Cited: 53
Multipeptide vaccination in cancer patients
Lorenzo Pilla, Licia Rivoltini, Roberto Patuzzo, et al.
Expert Opinion on Biological Therapy (2009) Vol. 9, Iss. 8, pp. 1043-1055
Closed Access | Times Cited: 60
Designing therapeutic cancer vaccines by mimicking viral infections
Hussein Sultan, Valentyna I. Fesenkova, Diane Addis, et al.
Cancer Immunology Immunotherapy (2016) Vol. 66, Iss. 2, pp. 203-213
Open Access | Times Cited: 47
Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis
Jochen T. Schaefer, James W. Patterson, Donna H. Deacon, et al.
Journal of Translational Medicine (2010) Vol. 8, Iss. 1
Open Access | Times Cited: 44
A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting
Andrew Gray, Adam B. Raff, Maurizio Chiriva‐Internati, et al.
Immunological Reviews (2008) Vol. 222, Iss. 1, pp. 316-327
Closed Access | Times Cited: 47
Peptide epitope identification for tumor-reactive CD4 T cells
Hiroya Kobayashi, Esteban Celis
Current Opinion in Immunology (2008) Vol. 20, Iss. 2, pp. 221-227
Open Access | Times Cited: 46
Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine
Junya Ohtake, Takayuki Ohkuri, Yuji Togashi, et al.
Immunology Letters (2014) Vol. 161, Iss. 1, pp. 20-30
Closed Access | Times Cited: 28
Systematic Review and Network Meta-Analysis of Overall Survival Comparing 3 mg/kg Ipilimumab With Alternative Therapies in the Management of Pretreated Patients With Unresectable Stage III or IV Melanoma
P. Dequen, Paul Lorigan, Jeroen P. Jansen, et al.
The Oncologist (2012) Vol. 17, Iss. 11, pp. 1376-1385
Open Access | Times Cited: 28
Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma
Ryo Ueda, Keri L. Low, Xinmei Zhu, et al.
Journal of Translational Medicine (2007) Vol. 5, Iss. 1
Open Access | Times Cited: 32
Melanoma vaccines: The problems of local immunosuppression
Marta E. Polak, Nicola Borthwick, Martine J. Jager, et al.
Human Immunology (2009) Vol. 70, Iss. 5, pp. 331-339
Closed Access | Times Cited: 28
Randomized clinical studies of anti-tumor vaccination: state of the art in 2008
Philippe Fournier, Volker Schirrmacher
Expert Review of Vaccines (2008) Vol. 8, Iss. 1, pp. 51-66
Closed Access | Times Cited: 26
HLA typing demands for peptide-based anti-cancer vaccine
Dirk Nagorsen, Eckhard Thiel
Cancer Immunology Immunotherapy (2008) Vol. 57, Iss. 12, pp. 1903-1910
Open Access | Times Cited: 24
HLA Class II Antigen Presentation in Prostate Cancer Cells: A Novel Approach to Prostate Tumor Immunotherapy
Bently P. Doonan, Azizul Haque
The Open Cancer Immunology Journal (2010) Vol. 3, Iss. 1, pp. 1-7
Open Access | Times Cited: 16
Artificially synthesized helper/killer-hybrid epitope long peptide (H/K-HELP): Preparation and immunological analysis of vaccine efficacy
Kazutaka Masuko, Daiko Wakita, Yuji Togashi, et al.
Immunology Letters (2014) Vol. 163, Iss. 1, pp. 102-112
Closed Access | Times Cited: 12
State of the science 60th anniversary review
Marie‐France Demierre, Michael S. Sabel, Kim Margolin, et al.
Cancer (2008) Vol. 113, Iss. S7, pp. 1728-1743
Open Access | Times Cited: 14
Identification of novel human leukocyte antigen‐A*11:01‐restricted cytotoxic T‐lymphocyte epitopes derived from osteosarcoma antigen papillomavirus binding factor
Dongliang Li, Shingo Toji, Kazue Watanabe, et al.
Cancer Science (2019) Vol. 110, Iss. 4, pp. 1156-1168
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top